Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bilateral Conjunctivitis (Disorder)
Conditions
Bilateral Conjunctivitis (Disorder)
Trial Timeline
Apr 30, 2021 → Sep 2, 2021
NCT ID
NCT04708821About Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7%
Dexamethasone ophthalmic insert 0.4Mg + 0.2% loteprednol etabonate ophthalmic suspension + olopatadine hydrochloride ophthalmic solution 0.7% is a approved stage product being developed by Ocular Therapeutix for Bilateral Conjunctivitis (Disorder). The current trial status is completed. This product is registered under clinical trial identifier NCT04708821. Target conditions include Bilateral Conjunctivitis (Disorder).
What happened to similar drugs?
0 of 1 similar drugs in Bilateral Conjunctivitis (Disorder) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04708821 | Approved | Completed |
Competing Products
3 competing products in Bilateral Conjunctivitis (Disorder)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 32 |
| ACT-774312 + Placebo | Idorsia | Phase 2 | 29 |
| cataract surgery | GenZum Life Sciences | Phase 3 | 30 |